Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Here's the question and answer session that followed the presentations by Drs. Ramaswamy Govindan and Julie Brahmer on the topic of immunotherapies for lung cancer. Below, you'll find the audio version of the podcast (there really wasn't any real video component for this one), along with the transcript for the program.
[powerpress]
Immunotherapies for LC Q and A Audio Podcast
Immunotherapies for LC Q and A Transcript
We've got a backlog of webinars and podcasts to get out to you, so I'm going to move forward on some more.
Thanks to LUNGevity Foundation for partnering with us on these programs.
Please feel free to offer comments and raise questions in our
discussion forums.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...